Search

Your search keyword '"Pal Saetrom"' showing total 9 results
Start Over Author "Pal Saetrom" Language undetermined
9 results on '"Pal Saetrom"'

1. Supplementary Figure 4 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

A) CT and MRI of patient with prolonged partial response with MTL-CEBPA treatment B) IFN-gamma, NFkB and IL6 trend at days 1, 8 and 15 following treatment and C) AFP change at from baseline to 4, 8 and 16 weeks on treatment

Published
2023
Full Text
View/download PDF

2. Supplementary Legends from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Supplementary Legends

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 5 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Showing complete radiological response of lung metastases

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 1 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Dose escalation flow chart. DLT - dose limiting toxicity, MTD - maximum tolerated dose

Published
2023
Full Text
View/download PDF

5. Appendix A from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Trial Protocol

Published
2023
Full Text
View/download PDF

6. Supplementary Tables from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Supplementary Table 1 CEBPA-51 PK parameters Supplementary Table 2 RECIST 1.1 response observed overall and per cohorts in HCC patients at cut-off (12 Sep 2018) presented as n (%)

Published
2023
Full Text
View/download PDF

7. Data from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Purpose:Transcription factor C/EBP-α (CCAAT/enhancer-binding protein alpha) acts as a master regulator of hepatic and myeloid functions and multiple oncogenic processes. MTL-CEBPA is a first-in-class small activating RNA oligonucleotide drug that upregulates C/EBP-α.Patients and Methods:We conducted a phase I, open-label, dose-escalation trial of MTL-CEBPA in adults with advanced hepatocellular carcinoma (HCC) with cirrhosis, or resulting from nonalcoholic steatohepatitis or with liver metastases. Patients received intravenous MTL-CEBPA once a week for 3 weeks followed by a rest period of 1 week per treatment cycle in the dose-escalation phase (3+3 design).Results:Thirty-eight participants have been treated across six dose levels (28–160 mg/m2) and three dosing schedules. Thirty-four patients were evaluable for safety endpoints at 28 days. MTL-CEBPA treatment–related adverse events were not associated with dose, and no maximum dose was reached across the three schedules evaluated. Grade 3 treatment-related adverse events occurred in nine (24%) patients. In 24 patients with HCC evaluable for efficacy, an objective tumor response was achieved in one patient [4%; partial response (PR) for over 2 years] and stable disease (SD) in 12 (50%). After discontinuation of MTL-CEBPA, seven patients were treated with tyrosine kinase inhibitors (TKIs); three patients had a complete response with one further PR and two with SD.Conclusions:MTL-CEBPA is the first saRNA in clinical trials and demonstrates an acceptable safety profile and potential synergistic efficacy with TKIs in HCC. These encouraging phase I data validate targeting of C/EBP-α and have prompted MTL-CEBPA + sorafenib combination studies in HCC.

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 3 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

Longitudinal changes in WBC mRNA expression of CEBPA, adenosine, PD-1 & CXCR4 at screening, day2, 8 and 15 of a single patient treated in the 130mg/m2 cohort

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 2 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Author

Nagy Habib, John J. Rossi, David C. Blakey, Hans E. Huber, Pal Saetrom, Chris Wood, Robert Habib, Jenni Vasara, Steve Felstead, Peter Lloyd, Pinelopi Andrikakou, Stephanie Dorman, Jon Voutila, Vikash Reebye, Sonia Fairbairn, Helen Glenny, Robert Nutbrown, David Collin, Joanna P. Nicholls, Vineet Kwatra, Sarah Hunter, James Spicer, David J. Pinato, Rohini Sharma, Madhava Pai, Duncan R.C. Spalding, T.R. Jeff Evans, Yuk Ting Ma, Daniel H. Palmer, Kai-Wen Huang, Cheng Ean Chee, Bristi Basu, Mikael H. Sodergren, Tim Meyer, Ruth Plummer, and Debashis Sarker

Abstract

qPCR of CEBPA mRNA levels at days 2, 8 and 15 following treatment

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results